2025
Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance.
De Placido P, Hughes M, Weipert C, Sammons S, Morganti S, Parsons H, Abravanel D, Giordano A, Smith K, Patel A, Kirkner G, Stever C, Suggs G, Sendrick K, Snow C, Winer E, Tolaney S, Lin N, Jeselsohn R. Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance. Journal Of Clinical Oncology 2025, 43: 1075-1075. DOI: 10.1200/jco.2025.43.16_suppl.1075.Peer-Reviewed Original ResearchMetastatic breast cancerCirculating tumor DNACopy number lossHR+/HER2- metastatic breast cancerAcquired ResistanceEndocrine therapyLiver metastasesGenomic profilingCDKN2A copy number lossHormone receptor-positive/HER2-negativePlasma circulating tumor DNADuration of endocrine therapyPresence of liver metastasesIntrinsic resistanceCompare genomic profilesBaseline TFPlasma samplesAcquired endocrine resistanceMetastatic breast cancer diagnosisStandard-of-careCox regression modelsESR1 fusionsTumor sheddingSecond-lineMedian durationTreatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy.
Lachowiez C, Barcellos A, Zettler C, Belli A, Fernandes L, Hansen E, Wang C, Owusu H, Zeidan A, Stein E, Swords R. Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy. JCO Oncology Practice 2025, op2400983. PMID: 40340477, DOI: 10.1200/op-24-00983.Peer-Reviewed Original ResearchVEN-based therapyTreatment patternsTime to next treatmentVenetoclax-based therapyVIALE-A trialEvent-free survivalLow-intensity regimensKaplan-Meier methodOutcomes of patientsInduction chemotherapyDiagnosed AMLIntensive chemotherapySecond-lineMutation statusFirst-lineInvestigational therapiesIndex dateMolecular subgroupsFLT3</i>-ITDNext treatmentDose informationTherapyAMLPatientsNovel treatmentPhase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03
Dowlati A, Chiang A, Cervantes A, Babu S, Hamilton E, Wong S, Tazbirkova A, Sullivan I, van Marcke C, Italiano A, Patel J, Mekan S, Wu T, Waqar S. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03. Journal Of Thoracic Oncology 2025, 20: 799-808. PMID: 39755168, DOI: 10.1016/j.jtho.2024.12.028.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsInvestigator-assessed objective response rateExtensive-stage SCLCObjective response rateProgression-free survivalPlatinum-sensitive diseaseSecond-line treatmentSacituzumab govitecanOverall survivalTreatment-related treatment-emergent adverse eventsExtensive-stage small cell lung cancerBlinded independent central review assessmentPhase 2 open-label studySmall cell lung cancerPlatinum-resistant diseaseSolid Tumors versionResponse Evaluation CriteriaPlatinum-based chemotherapySecond-line therapyCell lung cancerStudy of solid tumorsPartial responsePlatinum-sensitiveNeutropenic sepsisSecond-line
2024
Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding
Wang D, Wang D, Glaeser-Khan S, Moshashaian Asl R, Chetlapalli K, Ito S, Cuker A, Goshua G. Cost-Effectiveness of Oral Versus Intravenous First-Line Treatment of Severe Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding. Blood 2024, 144: 281-281. DOI: 10.1182/blood-2024-198803.Peer-Reviewed Original ResearchSevere iron deficiency anemiaHeavy menstrual bleedingIron deficiency anemiaOral ferrous sulfateIncremental cost-effectiveness ratioIV iron sucroseIV iron dextranFirst-line treatmentFirst-lineIron sucroseQuality-adjusted life expectancyOral ironSecond-lineDeterministic sensitivity analysisProbabilistic sensitivity analysesIron dextranMenstrual bleedingDeficiency anemiaIron deficiencyUS health system perspectiveTreated with oral ironIV iron supplementationIV iron treatmentOral iron therapyDevelopment of iron deficiencyNivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial
Wu J, Zhang S, Yu S, An G, Wang Y, Yu Y, Liang L, Wang Y, Xu X, Xiong Y, Shao D, Shi Z, Li N, Wang J, Jin D, Liu T, Cui Y. Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial. Nature Communications 2024, 15: 8876. PMID: 39406730, PMCID: PMC11480398, DOI: 10.1038/s41467-024-53109-4.Peer-Reviewed Original ResearchConceptsEsophageal squamous cell carcinomaAdvanced gastric adenocarcinomaSquamous cell carcinomaTyrosine kinase inhibitorsGastric adenocarcinomaVariant allele frequencyAnlotinib hydrochlorideCell carcinomaVascular endothelial growth factor inhibitorsAnti-PD-1 antibodySafety of nivolumabAnti-PD-1Disease control rateMedian overall survivalProgression-free survivalGrowth factor inhibitorsPhase II trialOverall response rateOASIS trialPD-1Second-lineOverall survivalImmune signaturesII trialFactor inhibitorsDocetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo P, Zarif T, McClure H, Davidsohn M, Eid M, Spinelli G, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre R, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E, Group S. Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study. Clinical Genitourinary Cancer 2024, 22: 102230. PMID: 39461026, DOI: 10.1016/j.clgc.2024.102230.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen receptor signaling inhibitorsCastration-resistant prostate cancerAbiraterone acetateOverall survivalProstate cancerElderly patientsSignaling InhibitorsCohort of consecutive patientsSecond-line therapyStandard first-lineReal-world studySecond-lineConsecutive patientsTreatment toxicityFirst-lineD. CONCLUSIONSPatient comorbiditiesIdentified patientsRetrospective designToxicity outcomesD groupInternational cohortPatientsNo differenceABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s462-s463. DOI: 10.1016/s2152-2650(24)01497-6.Peer-Reviewed Original ResearchLiso-celDuration of responseFollicular lymphomaBridging therapyBT subgroupR/R follicular lymphomaMedian Follow-UpHigh-risk populationSlow disease progressionFL diagnosisLisocabtagene maraleucelSecond-lineCR ratePrimary endpointSecondary endpointsInvestigator's discretionSafety profileFollow-upConsenting patientsDisease progressionSafety signalsOutpatient monitoringImprove outcomesResponse rateOutpatient settingImpact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study
Dahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s212. DOI: 10.1016/s2152-2650(24)00792-4.Peer-Reviewed Original ResearchAvelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
Motzer R, Penkov K, Uemura H, Campbell M, Kollmannsberger C, Lee J, Venugopal B, Van Den Eertwegh A, Negrier S, Gurney H, Albiges L, Berger R, Haanen J, Rini B, Larkin J, Schmidinger M, Sandner R, Wang J, Di Pietro A, CHOUEIRI T. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. Journal Of Clinical Oncology 2024, 42: 4508-4508. DOI: 10.1200/jco.2024.42.16_suppl.4508.Peer-Reviewed Original ResearchAdvanced renal cell carcinomaPD-L1+ tumorsProgression-free survivalOverall survivalJAVELIN RenalPD-L1Sunitinib armSafety profileFollow-upUntreated advanced renal cell carcinomaImmune checkpoint inhibitorsPD-(L)1 inhibitorsOverall populationSecond-line therapyMedian Follow-UpFirst-line treatmentPhase 3 trialRenal cell carcinomaInhibitor combination treatmentLong-term efficacySP263 assayCheckpoint inhibitorsPD-(L)1Data cutoffSecond-lineReal-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e181-e190. PMID: 38433043, DOI: 10.1016/j.clml.2024.01.010.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaHealthcare resource utilizationR-GEMOXOverall survivalR/R settingR/R diffuse large B-cell lymphomaElderly patientsLarge B-cell lymphomaDLBCL diagnosisRates of healthcare resource utilizationCombination of rituximabMedian overall survivalR/R DLBCL patientsB-cell lymphomaStem cell transplantationReal-world survivalHealthcare resource useSample of patientsMicro AbstractRelapsed/refractory settingDLBCL patientsThird-lineSecond-lineCell transplantationPost-index
2023
1990MO Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial
Dowlati A, Cervantes A, Babu S, Hamilton E, Wong S, Tazbirkova A, Sullivan I, de Lummen C, Italiano A, Patel J, Mekan S, Wu T, Chiang A. 1990MO Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial. Annals Of Oncology 2023, 34: s1061-s1062. DOI: 10.1016/j.annonc.2023.09.1221.Peer-Reviewed Original ResearchEvolving systemic management of urothelial cancers
Tan W, Tan M, Alhalabi O, Campbell M, Kamat A, Gao J. Evolving systemic management of urothelial cancers. Current Opinion In Oncology 2023, 35: 186-199. PMID: 36966497, DOI: 10.1097/cco.0000000000000942.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyInvasive bladder cancerBladder cancerAntibody-drug conjugatesFibroblast growth factor receptorCheckpoint inhibitorsUrothelial carcinomaProgrammed cell death-ligand 1 inhibitorsLocalized muscle invasive bladder cancerImprove bladder cancer outcomesNonmuscle invasive bladder cancerTraditional platinum-based chemotherapyProgrammed cell death 1Management of urothelial carcinomaMuscle invasive bladder cancerImmune checkpoint inhibitorsCell death 1Third-line optionBladder cancer outcomesResponse to therapyGrowth factor receptorFood and Drug AdministrationDeath-1Second-lineSystemic treatment
2022
AB0227 TREATMENT SEQUENCING PATTERNS AND COMPARATIVE EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM A REAL-WORLD SETTING
Ai L, Higashi M, Lee K, Liu Z, Jin L, Raja K, Mai Y, Jun T, Oh W, Beckmann A, Schadt E, Schadt Z, Wallsten R, Calay E, Kasarskis A, Pan Q, Schadt E, Wang X. AB0227 TREATMENT SEQUENCING PATTERNS AND COMPARATIVE EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM A REAL-WORLD SETTING. Annals Of The Rheumatic Diseases 2022, 81: 1241. DOI: 10.1136/annrheumdis-2022-eular.4655.Peer-Reviewed Original ResearchDisease-modifying antirheumatic drugsTime to next treatmentConventional synthetic DMARDsDurability of responseRheumatoid arthritisElectronic health recordsAntirheumatic drugsImproved duration of responseConventional synthetic disease-modifying antirheumatic drugsBiologic disease-modifying antirheumatic drugsSynthetic disease-modifying antirheumatic drugsPredictors of disease progressionSecond-line settingSecond-line therapyDuration of responseLines of therapyEuropean League Against RheumatismTime-to-event analysisMethods Electronic health recordsManagement of rheumatoid arthritisCsDMARD combinationSecond-lineAnti-TNFTNFi therapyImprove patient outcomes
2021
Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?
Lin J, Zhang Y, Hou W, Qin Q, Galsky M, Oh W, Tsao C. Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging? Journal Of Kidney Cancer 2021, 8: 13-19. PMID: 34722126, PMCID: PMC8523177, DOI: 10.15586/jkcvhl.v8i4.202.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaMetastatic renal cell carcinoma patientsCell carcinomaLymph nodesBone metastasesTreatment eraIncidence of metastases to lungRate of bone metastasesIncidence of bone metastasesPhase I-III clinical trialsPattern of metastasisMetastasis to lungLymph node metastasisBone imagingTime of regulatory approvalIncidence of boneCytokine eraMetastatic diseaseMetastatic patternSecond-lineLung metastasesTreatment modalitiesMetastatic distributionKinase inhibitors
2020
The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center.
Wong R, Wu J, Leen A, Tey G, Asokumaran Y, Chan G, Siddappan C, Jeyasekharan A, Chee C, Yong W, Ngiam K, Sundar R. The role of targeted therapy (TKI) in the treatment of advanced hepatocellular carcinoma (aHCC) in the era of immunotherapy: Real-world data using AI analytics from an academic medical center. Journal Of Clinical Oncology 2020, 38: e16623-e16623. DOI: 10.1200/jco.2020.38.15_suppl.e16623.Peer-Reviewed Original ResearchAdvanced hepatocellular carcinomaEra of immunotherapySequence of therapySystemic therapyOverall survivalHCC patientsClinical outcomesManagement of advanced hepatocellular carcinomaTreated with first-line immunotherapyTreatment of advanced hepatocellular carcinomaFirst-line immunotherapyFirst-line TKIsSecond-line immunotherapySecond-line TKIsLoco-regional therapiesProgression-free survivalSecond-line therapySecond-line treatmentPillar of treatmentChild-Pugh scoreMinority of patientsSecond-lineFirst-lineMedian ageTargeted therapy
2019
Evolving patterns of metastatic renal cell carcinoma: A meta-analysis.
Lin J, Oh W, Liaw B, Galsky M, Tsao C. Evolving patterns of metastatic renal cell carcinoma: A meta-analysis. Journal Of Clinical Oncology 2019, 37: 563-563. DOI: 10.1200/jco.2019.37.7_suppl.563.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRate of bone metastasesPattern of metastasisBone metastasesClinical trialsRate of lymph node metastasisPattern of metastatic diseaseFirst-line therapyLymph node metastasisRenal cell carcinomaClinical trial patientsTherapeutic clinical trialsRates of lungReport metastasisMetastatic diseaseSecond-lineLiver metastasesCell carcinomaFirst-lineNode metastasisTreatment eraBaseline characteristicsTreatment modalitiesEvaluate temporal trendsTrial patients
2017
Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.
Oh W, Cheng W, Miao R, Vekeman F, Gauthier-Loiselle M, Duh M, Drea E, Szatrowski T. Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices. Journal Of Clinical Oncology 2017, 35: 214-214. DOI: 10.1200/jco.2017.35.6_suppl.214.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerProstate-specific antigenOverall survivalOpioid useAndrogen receptor-targeted agentsPSA responseUS community oncology settingCastration-resistant prostate cancerResponse to first-lineLactate dehydrogenaseIncreased opioid useCox proportional hazards regression modelsECOG performance scoreReceptor-targeted agentsUS community oncology practicesNon-statistically significant trendProportional hazards regression modelsAlkaline phosphataseHazards regression modelsCommunity oncology settingImproved OSSecond-lineCommunity oncology practicesPrognostic featuresProstate cancer
2015
Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.
Oh W, Miao R, Duh M, Vekeman F, Sung J, Cheng W, Hennessy D, Gauthier-Loiselle M, Fortier J, Dhawan R. Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting. Journal Of Clinical Oncology 2015, 33: e16029-e16029. DOI: 10.1200/jco.2015.33.15_suppl.e16029.Peer-Reviewed Original Research
2008
Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer
Nakabayashi M, Sartor O, Jacobus S, Regan M, McKearn D, Ross R, Kantoff P, Taplin M, Oh W. Response to docetaxel/carboplatin‐based chemotherapy as first‐ and second‐line therapy in patients with metastatic hormone‐refractory prostate cancer. BJU International 2008, 101: 308-312. PMID: 18184327, DOI: 10.1111/j.1464-410x.2007.07331.x.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerProstate-specific antigenSecond-lineProstate cancerMetastatic hormone-refractory prostate cancerProstate-specific antigen levelGrade 4 toxicityMedian overall survivalPatients treated with DCSecond-line chemotherapyFirst-line chemotherapySecond-line therapyDana-Farber Cancer InstituteCarboplatin AUCOverall survivalChemotherapyDana-FarberIdentified patientsDC groupDocetaxelCarboplatinPatientsCancer InstituteEstramustineRegimens
2005
A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma
Rosenberg J, Galsky M, Rohs N, Weinberg V, Oh W, Kelly W, Small E. A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma. Cancer 2005, 106: 58-62. PMID: 16329138, DOI: 10.1002/cncr.21559.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate carcinomaProstate-specific antigenPSA decline >Clinical cross-resistanceTaxane chemotherapyProstate carcinomaProstate-specific antigen declines >PSA responseResponse to second-lineTime to PSA progressionRandomized phase II trialTaxane-resistant cell linesTaxane-based therapyFirst-line therapyKaplan-Meier methodIxabepilone treatmentPSA declinePSA progressionTaxane therapyMedian survivalSecond-lineChemotherapy responseIxabepiloneDisease progressionRetrospective evaluation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply